The Conversation (0)
ESSA Pharma released their financial results for their second quarter and provided an update on its clinical development program.
ESSA Pharma (NASDAQ:EPIX, TSX:EPI) released their financial results for their second quarter and provided an update on its clinical development program.
As quoted in the press release:
“We are pleased that EPI-506 continues to be well-tolerated, and that recent patient cohorts have achieved drug exposures within the targeted therapeutic range. We plan to treat additional patients at these drug levels, with our focus now being to augment our data set as we work to determine a dose selection for Phase 2,” said David R. Parkinson, MD, President and Chief Executive Officer of ESSA.
Clinical Development Update
ESSA initiated the Phase 1/2 clinical trial of EPI-506 in late 2015. The clinical trial is designed to demonstrate the safety, tolerability, maximum tolerated-dose, pharmacokinetics and efficacy of EPI-506 in the treatment of prostate cancer patients who have failed treatments with abiraterone or enzalutamide or both, the current standard-of-care drugs in metastatic castrate-resistant prostate cancer (“mCRPC”).
Click here to read the full press release.
Source: www.newswire.ca
